An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?
Nature Biotechnology, Vol.37, No. 1, pp. 21-22 (2019); DOI: 10.1038/nbt.4324
Posted: 27 Jun 2019
There are 2 versions of this paper
An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?
Nature Biotechnology, Vol.37, No. 1, pp. 21-22 (2019); DOI: 10.1038/nbt.4324
Posted: 27 Jun 2019
You are currently viewing this paper
An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?
Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.
Posted: 24 Apr 2019
Date Written: January 3, 2019
Abstract
A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
Suggested Citation: Suggested Citation
Minssen, Timo and Kesselheim, Aaron S. and Darrow, Jonathan J., An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit? (January 3, 2019). Nature Biotechnology, Vol.37, No. 1, pp. 21-22 (2019); DOI: 10.1038/nbt.4324
, Available at SSRN: https://ssrn.com/abstract=3409911